Biomarin Pharmaceutical Inc (BMRN)
Fixed asset turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 2,845,320 | 2,374,190 | 2,068,670 | 1,832,750 | 1,823,140 |
| Property, plant and equipment | US$ in thousands | 1,043,040 | 1,066,130 | 1,073,370 | 1,035,460 | 1,032,470 |
| Fixed asset turnover | 2.73 | 2.23 | 1.93 | 1.77 | 1.77 |
December 31, 2024 calculation
Fixed asset turnover = Revenue ÷ Property, plant and equipment
= $2,845,320K ÷ $1,043,040K
= 2.73
Biomarin Pharmaceutical Inc's fixed asset turnover ratio demonstrates a positive trend over the years, indicating an improvement in the company's efficiency in generating revenue from its fixed assets.
The fixed asset turnover ratio remained stable at 1.77 for both December 31, 2020, and 2021. However, there was a noticeable increase in efficiency as the ratio increased to 1.93 by December 31, 2022. This uptick suggests that Biomarin Pharmaceutical Inc was able to generate $1.93 in revenue for every dollar invested in fixed assets.
Moreover, the trend continued to show significant improvement as the fixed asset turnover ratio further increased to 2.23 by December 31, 2023, and then to 2.73 by December 31, 2024. This indicates that the company effectively utilized its fixed assets to generate more revenue.
Overall, the increasing trend in Biomarin Pharmaceutical Inc's fixed asset turnover ratio reflects the company's ability to efficiently use its fixed assets to drive revenue growth, which is a positive signal for investors and stakeholders in assessing the company's operational performance.
Peer comparison
Dec 31, 2024